LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 87

Search options

  1. Book: Tofacitinib (Xeljanz)

    Neurath, Markus

    der erste Januskinase-Inhibitor in der Therapie von Colitis ulcerosa

    (Case report ; 10. Jahrgang, Heft 12 (September 2018))

    2018  

    Author's details Herausgeber Prof. Dr. Markus Neurath
    Series title Case report ; 10. Jahrgang, Heft 12 (September 2018)
    Collection
    Language German
    Size 15 Seiten, Illustrationen
    Publisher Thieme
    Publishing place Stuttgart
    Publishing country Germany
    Document type Book
    HBZ-ID HT019821077
    Database Catalogue ZB MED Medicine, Health

    Kategorien

  2. Article ; Online: Chronisch-entzündliche Darmerkrankungen.

    Atreya, Raja / Neurath, Markus Friedrich

    Deutsche medizinische Wochenschrift (1946)

    2022  Volume 147, Issue 6, Page(s) 295–300

    Abstract: Growing insights into the underlying immunopathogenesis of inflammatory bowel diseases (IBD) have led to the advent of targeted therapies, which selectively target pivotal mediators of the inflammatory process. This has enabled us to define and achieve ... ...

    Title translation Inflammatory bowel diseases - therapy update 2022.
    Abstract Growing insights into the underlying immunopathogenesis of inflammatory bowel diseases (IBD) have led to the advent of targeted therapies, which selectively target pivotal mediators of the inflammatory process. This has enabled us to define and achieve novel therapeutic outcomes to prevent disease-associated complications and halt the progressive course of disease. In addition to already available treatment options, the selective Janus kinase type 1 inhibitor filgotinib and the selective sphingosine-1-phosphate receptor modulator Ozanimod have recently been approved for the treatment of ulcerative colitis patients. Furthermore, positive phase 2/3 induction and maintenance trial results have been reported for representatives of the class of IL-23p19 inhibitors, which are expected to further increase our therapeutic possibilities. All these agents can be applied as first-line or also subsequent treatment options and recent head-to-head trials have helped us to position these substances in our therapeutic algorithm. Nevertheless, there is still the currently unmet clinical need do establish predictive markers of response to identify the subgroup of IBD patients, that have a heightened probability of response to each therapy. In the following, we will give an overview of the recently approved or in late-stage clinical development tested substances and discuss their positioning in our therapeutic armamentarium.
    MeSH term(s) Colitis, Ulcerative/drug therapy ; Humans ; Immunologic Factors/therapeutic use ; Inflammatory Bowel Diseases/drug therapy ; Janus Kinase Inhibitors/therapeutic use
    Chemical Substances Immunologic Factors ; Janus Kinase Inhibitors
    Language German
    Publishing date 2022-03-15
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 200446-x
    ISSN 1439-4413 ; 0012-0472
    ISSN (online) 1439-4413
    ISSN 0012-0472
    DOI 10.1055/a-1585-4026
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Book: Checkliste Anamnese und klinische Untersuchung

    Neurath, Markus / Lohse, Ansgar W. / Akat, Kemal Marc / Debrezion, Johannes

    (Checklisten der aktuellen Medizin)

    2018  

    Title variant Anamnese und klinische Untersuchung
    Author's details Markus F. Neurath, Ansgar W. Lohse, Kemal Akat [und weitere] ; Mitarbeiter früherer Auflagen: J. Debrezion [und weitere]
    Series title Checklisten der aktuellen Medizin
    Keywords Anamnese ; Untersuchung
    Subject Krankenuntersuchung ; Ärztliche Untersuchung ; Medizinische Untersuchung ; Ärztliche Untersuchungstechnik ; Klinische Untersuchung ; Körperliche Untersuchung ; Anamneseerhebung
    Language German
    Size 534 Seiten, Illustrationen, 18 cm x 11 cm
    Edition 5., aktualisierte Auflage
    Publisher Georg Thieme Verlag
    Publishing place Stuttgart ; New York
    Publishing country Germany
    Document type Book
    Note Auf dem Umschlag: + Online-Version in der eRef
    Old title Vorangegangen ist Checkliste Anamnese und klinische Untersuchung
    HBZ-ID HT019839973
    ISBN 978-3-13-241979-7 ; 3-13-241979-6 ; 9783132419803 ; 9783132419810 ; 313241980X ; 3132419818
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

  4. Article ; Online: Genomic signatures of globally enhanced gene duplicate accumulation in the megadiverse higher Diptera fueling intralocus sexual conflict resolution

    Riyue Bao / Markus Friedrich

    PeerJ, Vol 8, p e

    2020  Volume 10012

    Abstract: Gene duplication is an important source of evolutionary innovation. To explore the relative impact of gene duplication during the diversification of major insect model system lineages, we performed a comparative analysis of lineage-specific gene ... ...

    Abstract Gene duplication is an important source of evolutionary innovation. To explore the relative impact of gene duplication during the diversification of major insect model system lineages, we performed a comparative analysis of lineage-specific gene duplications in the fruit fly Drosophila melanogaster (Diptera: Brachycera), the mosquito Anopheles gambiae (Diptera: Culicomorpha), the red flour beetle Tribolium castaneum (Coleoptera), and the honeybee Apis mellifera (Hymenoptera). Focusing on close to 6,000 insect core gene families containing maximally six paralogs, we detected a conspicuously higher number of lineage-specific duplications in Drosophila (689) compared to Anopheles (315), Tribolium (386), and Apis (223). Based on analyses of sequence divergence, phylogenetic distribution, and gene ontology information, we present evidence that an increased background rate of gene duplicate accumulation played an exceptional role during the diversification of the higher Diptera (Brachycera), in part by providing enriched opportunities for intralocus sexual conflict resolution, which may have boosted speciation rates during the early radiation of the megadiverse brachyceran subclade Schizophora.
    Keywords Gene duplication ; Drosophila ; Brachycera ; Genome evolution ; Energy metabolism ; Sexual conflict resolution ; Medicine ; R ; Biology (General) ; QH301-705.5
    Language English
    Publishing date 2020-10-01T00:00:00Z
    Publisher PeerJ Inc.
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  5. Book: Checkliste Anamnese und klinische Untersuchung

    Neurath, Markus / Lohse, Ansgar W.

    (Checklisten der aktuellen Medizin)

    2015  

    Title variant Anamnese und klinische Untersuchung
    Author's details Ansgar W. Lohse, Markus F. Neurath
    Series title Checklisten der aktuellen Medizin
    Keywords Checkliste ; Anamnese ; Untersuchung
    Subject Krankenuntersuchung ; Ärztliche Untersuchung ; Medizinische Untersuchung ; Ärztliche Untersuchungstechnik ; Klinische Untersuchung ; Körperliche Untersuchung ; Anamneseerhebung
    Language German
    Size 533 S. : zahlr. Ill., graph. Darst.
    Edition 4., aktualisierte und überarb. Aufl.
    Publisher Thieme
    Publishing place Stuttgart u.a.
    Publishing country Germany
    Document type Book
    Accompanying material Zugang zu iOS-App über Code
    New title 5. Aufl. u.d.T. Neurath, Markus: Checkliste Anamnese und klinische Untersuchung
    HBZ-ID HT018602136
    ISBN 978-3-13-127334-5 ; 3-13-127334-8 ; 978-3-13-152034-0 ; 978-3-13-200394-1 ; 3-13-152034-5 ; 3-13-200394-8
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

  6. Book ; Thesis: Kontinuierliche nicht-invasive Blutdruckmessung mit dem Portapres-System bei Schlafapnoe

    Mayweg, Markus Friedrich

    (Wissenschaft in Dissertationen ; 561)

    2000  

    Author's details von Markus Friedrich Mayweg
    Series title Wissenschaft in Dissertationen ; 561
    Collection
    Keywords Portapres ; Schlafapnoe
    Subject Schlafapnoe-Syndrom ; Obstruktives Schlaf-Apnoe-Syndrom ; Portaprex-System
    Language German
    Size 88 S., graph. Darst., 21 cm
    Publisher Görich und Weiershäuser
    Publishing place Marburg
    Publishing country Germany
    Document type Book ; Thesis
    Thesis / German Habilitation thesis Marburg, Univ., Diss., 2000
    HBZ-ID HT012951367
    ISBN 3-89703-387-9 ; 978-3-89703-387-0
    Database Catalogue ZB MED Medicine, Health

    Kategorien

  7. Book ; Thesis: Die Wirkung von Acetazolamid auf die zerebrale Mikrozirkulation von Kaninchen

    Börschel, Markus Friedrich

    2000  

    Author's details vorgelegt von Markus Friedrich Börschel
    Language German
    Size 55 S. : graph. Darst.
    Publishing country Germany
    Document type Book ; Thesis
    Thesis / German Habilitation thesis München, Univ., Diss., 2000
    HBZ-ID HT012879279
    Database Catalogue ZB MED Medicine, Health

    Kategorien

  8. Article: Chronisch-entzündliche Darmerkrankungen

    Atreya, Raja / Neurath, Markus Friedrich

    DMW - Deutsche Medizinische Wochenschrift

    2022  Volume 147, Issue 06, Page(s) 295–300

    Abstract: Chirurgische Therapie: Die Auswertung von Langzeitdaten bestätigt die Gleichwertigkeit der primär chirurgischen vs. medikamentösen (Infliximab) Therapie bei Morbus-Crohn-Patienten mit isoliertem Ileozökalbefall.: Neu zugelassene und sich in später ... ...

    Abstract Chirurgische Therapie: Die Auswertung von Langzeitdaten bestätigt die Gleichwertigkeit der primär chirurgischen vs. medikamentösen (Infliximab) Therapie bei Morbus-Crohn-Patienten mit isoliertem Ileozökalbefall.
    Neu zugelassene und sich in später klinischer Entwicklung befindliche Therapien: Der selektive JAK-1-Inhibitor Filgotinib ist kürzlich zur Behandlung von Colitis-ulcerosa-Patienten mit mittelschwerer bis schwerer Aktivität zugelassen worden, welche auf eine konventionelle oder biologische Therapie nicht angesprochen haben. Weiterhin ist der S1P-Rezeptor-Modulator Ozanimod, welcher den Abstrom von Lymphozyten aus dem Lymphknoten verhindert, ebenfalls zur Behandlung der genannten Colitis-ulcerosa-Patienten zugelassen worden. Der S1P-Rezeptor-Modulator Etrasimod wird aktuell in einer klinischen Phase-3-Studie bei Colitis ulcerosa getestet und der selektive JAK-1-Inhibitor Upadacitinib dürfte nächstes Jahr bei Colitis ulcerosa zugelassen werden. Zahlreiche IL-23p19-Inhibitoren befinden sich in fortgeschrittenen Studienphasen (Guselkumab, Mirikizumab, Brazikumab) bzw. haben diese bereits beendet (Risankizumab). Deren Zulassung ist zeitnah zu erwarten. Der lokal applizierbare Toll-like-Rezeptor-9-Agonist Cobitolimod könnte zukünftig eine lokal applizierbare Therapieoption bei Patienten mit linksseitiger Colitis ulcerosa darstellen.
    Zukünftige therapeutische Herausforderungen: Die Positionierung der bereits vorhandenen und zukünftigen Therapieoptionen in unseren Therapiealgorithmus muss noch definiert werden. Hierbei können wir auf Ergebnisse erster Head-to-Head-Studien zurückgreifen und sollten darüber hinaus bei jedem Patienten individuelle Faktoren berücksichtigen. Noch immer fehlen Prädiktoren für die Vorhersage des individuellen Therapieansprechens.
    Keywords Morbus Crohn ; Colitis ulcerosa ; JAK-1-Inhibitor ; IL-23-Inhibitor ; Cobitolimod ; Crohn’s disease ; ulcerative colitis ; JAK-1 inhibitor ; IL-23 inhibitor ; Cobitolimod
    Language German
    Publishing date 2022-03-01
    Publisher Georg Thieme Verlag KG
    Publishing place Stuttgart ; New York
    Document type Article
    ZDB-ID 200446-x
    ISSN 1439-4413 ; 0012-0472
    ISSN (online) 1439-4413
    ISSN 0012-0472
    DOI 10.1055/a-1585-4026
    Database Thieme publisher's database

    More links

    Kategorien

  9. Article ; Online: Maximum Heart Rate- and Lactate Threshold-Based Low-Volume High-Intensity Interval Training Prescriptions Provide Similar Health Benefits in Metabolic Syndrome Patients

    Dejan Reljic / Fabienne Frenk / Hans Joachim Herrmann / Markus Friedrich Neurath / Yurdagül Zopf

    Healthcare, Vol 11, Iss 711, p

    2023  Volume 711

    Abstract: Exercise is an integral part of metabolic syndrome (MetS) treatment. Recently, low-volume high-intensity interval training (LOW-HIIT) has emerged as a time-efficient approach to improving cardiometabolic health. Intensity prescriptions for LOW-HIIT are ... ...

    Abstract Exercise is an integral part of metabolic syndrome (MetS) treatment. Recently, low-volume high-intensity interval training (LOW-HIIT) has emerged as a time-efficient approach to improving cardiometabolic health. Intensity prescriptions for LOW-HIIT are typically based on maximum heart rate (HR max ) percentages. However, HR max determination requires maximal effort during exercise testing, which may not always be feasible/safe for MetS patients. This trial compared the effects of a 12-week LOW-HIIT program based on: (a) HR max (HIIT-HR), or (b) submaximal lactate threshold (HIIT-LT), on cardiometabolic health and quality of life (QoL) in MetS patients. Seventy-five patients were randomized to HIIT-HR (5 × 1 min at 80–95% HR max ), HIIT-LT (5 × 1 min at 95–105% LT) groups, both performed twice weekly on cycle ergometers, or a control group (CON). All patients received nutritional weight loss consultation. All groups reduced their body weight (HIIT-HR: −3.9 kg, p < 0.001; HTT-LT: −5.6 kg, p < 0.001; CON: −2.6 kg, p = 0.003). The HIIT-HR and HIIT-LT groups similarly, improved their maximal oxygen uptake (+3.6 and +3.7 mL/kg/min, p < 0.001), glycohemoglobin (−0.2%, p = 0.005, and −0.3%, p < 0.001), homeostasis model assessment index (−1.3 units, p = 0.005, and −1.0 units, p = 0.014), MetS z-score (−1.9 and −2.5 units, p < 0.001) and QoL (+10 points, p = 0.029, and +11 points, p = 0.002), while the CON did not experience changes in these variables. We conclude that HIIT-LT is a viable alternative to HIIT-HR for patients who are not able/willing to undergo maximal exercise testing.
    Keywords obesity ; cardiometabolic health ; quality of life ; interval training ; exercise prescription ; cardiorespiratory fitness ; Medicine ; R
    Subject code 796
    Language English
    Publishing date 2023-02-01T00:00:00Z
    Publisher MDPI AG
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  10. Book ; Thesis: Expression von Zytokinrezeptoren in Plazenta und Eihaut im Verlauf der normalen Schwangerschaft und in Abhängigkeit vorzeitiger und zeitgerechter Wehentätigkeit

    Geiße, Markus Friedrich

    1998  

    Author's details vorgelegt von Markus Friedrich Geiße
    Language German
    Size 66 S. : Ill., graph. Darst.
    Document type Book ; Thesis
    Thesis / German Habilitation thesis Frankfurt am Main, Univ., Diss., 1999
    HBZ-ID HT011242184
    Database Catalogue ZB MED Medicine, Health

    Kategorien

To top